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Introduction
In the field of drug delivery liposomes are predominantly used as carriers for hydrophilic molecules that are entrapped within their aqueous inner volume. Long circulating poly(ethylene glycol) modified liposomes with the cytotoxic drug doxorbicine are an example of such a clinically used formulation.
1 Highly lipophilic drugs can only be used therapeutically by addition of possibly toxic solubilizing agents or by development of complex pharmaceutical formulations. One way of overcoming these disadvantages is the incorporation of such drugs into the bilayer matrix of phospholipid liposomes.
We chose the approach of the chemical transformation of water-soluble nucleosides of known cytotoxic properties into lipophilic drugs or prodrugs. Due to the insolubility of these compounds we developed formulations that can be used for intravenous applications in which the lipophilic molecules are incorporated into lipid bilayer membranes of small unilamellar liposomes. Initially we chose 1-β-D-arabinofuranosylcytosine (ara-C) as cytotoxic nucleoside because the major untoward properties of the drug are the short plasma half-life and rapid degradation by deamination to the inactive metabolite 1-β-D-arabinofuranosyluracil (ara-U), a disadvantage that also impedes the oral application of ara-C.
To abolish these shortcomings a large number of 5'-and N 4 -substituted ara-C derivatives have been synthesized and characterized in the past. We demonstrated that N 4 -acyl-derivatives of ara-C were active in vivo as liposomal formulations at concentrations 2 -4 times lower than ara-C. 2 However, the protection of the N 4 -acylara-C derivatives against enzymatic deamination was only partially achieved and -2 -suggested to be insufficient for a significant improvement of the cytotoxic properties.
Based on these findings, we synthesized a new class of N 4 -alkyl-ara-C derivatives. 3, 4 These compounds show a typical structure-activity correlation between the length of the alkyl side chain and their anti-tumor activity. 3 The most effective derivative, N 4 -octadecyl-ara-C (NOAC) is highly lipophilic and extremely resistant towards deamination. 5 NOAC exerts excellent anti-tumor activity after oral and parenteral therapy. [6] [7] [8] In a recent study the activity of NOAC against freshly explanted clonogenic cells from human tumors was determined and compared with conventional anti-tumor agents. NOAC was used in two liposomal preparations, a stable lyophilized and a freshly prepared liquid formulation. Both formulations inhibited tumor colony formation equally in a concentration-dependent fashion. At optimal conditions liposomal NOAC had a significantly better activity compared to the clinically used drugs cisplatin, doxorubicin, 5-fluorouracil, gemcitabine, mitomycin C and etoposide. Furthermore, in a hematopoietic stem cell assay NOAC was less toxic than ara-C and doxorubicin by factors ranging from 2.5 to 200, indicating that this drug is well tolerated at high doses.
9
In contrast to the parent drug ara-C, the cellular uptake of NOAC is nucleosidetransporter independent and only insignificant amounts are phosphorylated to ara-C triphosphate (ara-CTP). Furthermore, NOAC is cytotoxic in ara-C resistant HL-60 cells 10, 11 and treatment of multidrug resistant tumor cells did not induce P-170 glycoprotein expression, suggesting that the N 4 -alkyl-ara-C derivatives are able to circumvent MDR1 multidrug resistance. 12 We conclude therefore that the mechanisms of action of the N 4 -alkyl-ara-C derivatives are different from ara-C. -4 -
Materials and Methods

Chemicals
Soy phosphatidylcholine (SPC) was obtained from L. Meyer, Hamburg, Germany.
Cholesterol (Fluka AG, Buchs, Switzerland) was re-crystallized from methanol.
Poly(ethylene glycol)-dipalmitoylphosphatidyl ethanolamine (PEG-DPPE, M r 2750) was synthesized as described. 13 DL-α -Tocopherol, all buffer salts and other chemicals used were of analytical grade and obtained from Merck, Darmstadt, Germany or Fluka. Munich, Germany). Larger volumes (50-500 ml) of liposomes are prepared using a capillary dialysis instrument. 16 The resulting liposomes are sterile filtrated (0.2 µm, Gelman Sciences, Ann Arbor, MI), filled at appropriate volumes (e.g. 10 ml liposomes with 5 mg NOAC/ml) into sterile vials, frozen in liquid nitrogen and lyophilized during 28-48 h (Dura-Dry TM lyophilizer, FTS Systems, New York).
Synthesis
-6 - The 
Properties of NOAC and the duplex drugs
The cytotoxic activity of the nucleoside drugs was tested in vitro on human tumor cell lines using a dye reduction assay. 19, 20 The IC 50 values for NOAC and the duplex drugs are summarized in Table I . Furthermore, the anti-tumor activity of NOAC and the duplex drugs ara-C-NOAC and 5-FdU-NOAC were confirmed by the National Cancer -7 -Institute (NCI) in vitro drug screening program where they were found to be active against several types of human tumors. 21 In an experiment using the L1210 mouse leukemia model we compared the cytotoxic activity of NOAC formulated in plain and in PEG-liposomes of 80-160 nm mean diameter. As summarized in Table II, In an in vivo experiment a human acute lymphatic leukemia (ALL) xenotransplanted to NOD/SCID-3 mice was used to evaluate the anti-leukemic effect of NOAC in -8 -comparison to standard agents. As summarized in Table III liposomal NOAC induced the prevention of leukemia development without causing severe side effects at lower doses. The prevention of peritoneal tumors and ascites in the ALL-SCID-3 model was achieved with 8-fold lower drug concentrations of liposomal NOAC as compared to ara-C. 22 In several aspects, the lipophilic ara-C derivative NOAC was found to have different pharmacological effects as compared to ara-C. Total uptake after incubation of liposomal NOAC with tumor cells was generally 5-10-fold higher as ara-C. NOAC distributes to more than 90% into the membrane fraction of a cell extract, whereas ara-C is distributed by more than 95% to the cytoplasmic fraction. Furthermore, the uptake mechanism of NOAC was shown to be independent of the nucleoside transport mechanism involved for ara-C and known to be sensitive to dipyridamole and deoxycytidine. NOAC uptake and cytotoxicity were not decreased in the presence of these blocking agents. NOAC is not a substrate for deoxycytidine kinase, the key enzyme of ara-C phosphorylation, suggesting other mechanisms of action. 5, 6, 10 NOAC has several advantages compared to other lipophilic ara-C derivatives such as ara-C ocfosfate (ara-CMP-stearyl ester, YNK-01) 23 and thioether-linked lipid conjugates 24 which are orally active prodrugs of ara-C. NOAC is both orally and parenterally active, whereas ara-C ocfosfate and and the thioether-linked lipid
conjugates cannot be applied parenterally due to their hemolytic toxicity. Furthermore, NOAC is active against solid and drug resistant tumors, whereas cytarabine ocfosfate and BH-AC are classical prodrugs of ara-C with an activity spectrum that is not -9 -significantly different from the parent drug. In an experimental phase I study with liposomal NOAC the plasma elimination half-life in cancer patients ranged between 11-16 h with peak plasma levels of 180-240 µ M at 600 mg NOAC/m 2 without untoward toxic effects, warranting further clinical development of this new drug. 25 The duplex drugs were found to be strong inhibitors of the cell cycle. They mainly arrest tumor cells in the early S-phase. 19, 20 With the duplex drugs cell uptake, intracellular distribution and fate and metabolism were not yet investigated. However, due to their similarity to NOAC it can be assumed that they have comparable properties. 5-FdU-NOAC was found overcome 5-FdU resistance in p53 mutated and androgenindependent DU-145 and PC-3 cells. 20 It is likely that the heteronucleoside dimer is cleaved to 5-FdUMP and NOAC, resulting in sustained intracellular drug concentrations over an extended period, consequently increasing duration and magnitude of the cytotoxic effect. This hypothesis is supported by the fact that the duplex drug specifically inhibits TS activity (see Table I ) and that it exerts a cell cycle phase- 
Distribution of NOAC to blood cells and plasma proteins
An important finding was that NOAC is not tightly anchored to the liposomal lipid bilayer and thus is readily distributed in the blood mainly into erythrocyte membranes and lipoproteins. 27 It is known that unilamellar liposomes aggregate with LDL and allow the transfer of incorporated drugs from the liposomes to LDL. Similar to the observation of others for other lipophilic drugs, 28 we found that after intravenous injection of liposomal NOAC the drug is transferred within short time from the liposome bilayers to erythrocyte membranes (30%), plasma proteins (<67%) and leukocytes (<2%). Table II ). This property can be explained with the in vivo distribution experiments and the in vitro incubation studies with plasma where we observed a fast transfer of NOAC from the liposome membranes to plasma proteins and erythrocytes. 27, 29 Thus, the liposomes serve mainly as a pharmaceutical formulation to permit solubilisation and parenteral administration of the new derivatives.
In conclusion, the chemical modification of water-soluble molecules by attachment of long alkyl chains and their stable incorporation into the bilayer membranes of small unilamellar liposomes represent a very promising method for the development of new drugs not only for the treatment of tumors or infections, but also for many other diseases. Tables   Table I In vitro cytotoxicity (IC 50 ) and inhibition of thymidylate synthase (TS) on DU-145 and PC-3 prostate tumor cells by the duplex drugs in comparison to 5-FdU, ara-C and NOAC Table II Cytostatic activity of NOAC in plain and in PEG-liposomes in the L1210 mouse leukemia model after intravenous therapy on days 2 and 6. Table III Antileukemic activity of liposomal NOAC in the ALL-SCID-3 leukemia model Inhibition of tumor colony forming by NOAC from freshly explanted human tumors Treatment started on day 1. Treatment schedule was on day 1, 4, 7, 11 after tumor inoculation.
Legends to Figures and
b Average tumor burden given as sum of peritoneal ascites fluid and solid tumor nodules in ml or gram per mouse.
c 3 of 6 mice died due to toxicity.
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